Ironwood Pharmaceuticals, Inc. (IRWD)

7,88 0,00 (0,00%) In data: 12:54PM EDT. Mercato aperto.

Ironwood Pharmaceuticals, Inc.

100 Summer Street
Suite 2300
Boston, MA 02110
United States
617 621 7722
https://www.ironwoodpharma.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 267

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas A. McCourt	CEO & Director	1,61M	46,82k	1957
Mr. Sravan Kumar Emany	Senior VP, Principal Financial Officer & CFO	913,88k	N/D	1978
Mr. John Minardo	Senior VP, Chief Legal Officer & Secretary	814,41k	N/D	1976
Dr. Michael Shetzline M.D., Ph.D.	Chief Medical Officer, Senior VP and Head of Research & Drug Development	860,45k	N/D	1959
Mr. Andrew Davis	Senior VP & Chief Business Officer	824,36k	N/D	1987
Mr. Ronald Silver	Corporate Controller & Principal Accounting Officer	N/D	N/D	1983
Mr. Marcel Moulaison	Vice President of Technical Operations	N/D	N/D	N/D
Greg Martini	Vice President of Strategic Finance & Investor Relations	N/D	N/D	N/D
Ms. Beth Calitri	Head of Corporate Communications & Media Relations	N/D	N/D	N/D
Mr. Mike Nanfito	Vice President of Sales & Sales Excellence	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Ironwood Pharmaceuticals, Inc. al 29 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 6; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.